Index -
P/E -
EPS (ttm) -0.52
Insider Own 10.73%
Shs Outstand 71.42M
Perf Week 4.21%
Market Cap 301.37M
Forward P/E -
EPS next Y -0.52
Insider Trans 208.70%
Shs Float 63.76M
Perf Month 118.78%
Income -37.00M
PEG -
EPS next Q -0.25
Inst Own 75.64%
Short Float 2.45%
Perf Quarter 244.35%
Sales 27.08M
P/S 11.13
EPS this Y 41.73%
Inst Trans 52.48%
Short Ratio 0.72
Perf Half Y 280.77%
Book/sh 1.82
P/B 2.17
EPS next Y 29.73%
ROA -18.47%
Short Interest 1.56M
Perf Year 352.73%
Cash/sh 1.68
P/C 2.36
EPS next 5Y -
ROE -25.83%
52W Range 0.80 - 5.17
Perf YTD 277.14%
Dividend Est. -
P/FCF -
EPS past 5Y 20.67%
ROI -27.95%
52W High -23.40%
Beta 0.46
Dividend TTM -
Quick Ratio 7.03
Sales past 5Y 74.29%
Gross Margin 53.53%
52W Low 395.00%
ATR (14) 0.45
Dividend Ex-Date -
Current Ratio 7.03
EPS Y/Y TTM 68.83%
Oper. Margin -208.45%
RSI (14) 63.70
Volatility 10.36% 16.07%
Employees 91
Debt/Eq 0.02
Sales Y/Y TTM 26.35%
Profit Margin -136.65%
Recom 1.57
Target Price 7.60
Option/Short Yes / Yes
LT Debt/Eq 0.02
EPS Q/Q 74.27%
Payout -
Rel Volume 0.49
Prev Close 4.07
Sales Surprise 175.94%
EPS Surprise -1829.82%
Sales Q/Q -53.18%
Earnings Nov 06 BMO
Avg Volume 2.17M
Price 3.96
SMA20 25.95%
SMA50 94.10%
SMA200 179.77%
Trades
Volume 1,052,033
Change -2.70%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-20-24 Upgrade
Cantor Fitzgerald
Neutral → Overweight
Nov-19-24 Upgrade
Leerink Partners
Market Perform → Outperform
$2 → $7
Nov-19-24 Upgrade
Jefferies
Hold → Buy
$2 → $7
Nov-19-24 Upgrade
BTIG Research
Neutral → Buy
$8
Nov-18-24 Upgrade
Piper Sandler
Neutral → Overweight
$3 → $13
Jan-22-24 Downgrade
H.C. Wainwright
Buy → Neutral
Nov-13-23 Downgrade
William Blair
Outperform → Mkt Perform
Oct-03-23 Initiated
Evercore ISI
Outperform
$22
Dec-14-22 Initiated
Stifel
Buy
$29
Dec-01-22 Initiated
Goldman
Buy
$25
Oct-06-22 Initiated
BTIG Research
Buy
$32
Jul-23-21 Resumed
Jefferies
Buy
$27 → $32
Jun-15-21 Initiated
Piper Sandler
Overweight
$30
Apr-21-21 Initiated
H.C. Wainwright
Buy
$40
Oct-22-19 Upgrade
SVB Leerink
Mkt Perform → Outperform
Sep-06-19 Downgrade
JMP Securities
Mkt Outperform → Mkt Perform
Jun-27-19 Downgrade
SVB Leerink
Outperform → Mkt Perform
May-06-19 Initiated
SVB Leerink
Outperform
$13
Mar-28-18 Resumed
Leerink Partners
Outperform
$52
Feb-09-18 Initiated
Guggenheim
Buy
$53
Show Previous Ratings
Nov-26-24 04:30PM
(GlobeNewswire) -9.02%
+5.23%
Nov-20-24 05:11AM
Nov-19-24 09:30PM
03:27PM
11:00AM
(Pharmaceutical Technology)
08:50AM
Loading…
Nov-18-24 08:50AM
08:10AM
08:10AM
Nov-06-24 08:05AM
07:07AM
(Associated Press Finance)
07:00AM
Oct-09-24 07:02PM
Sep-18-24 06:52AM
Sep-17-24 07:00AM
Sep-10-24 07:00AM
08:15AM
Loading…
Aug-07-24 08:15AM
07:20AM
(Associated Press Finance)
07:00AM
Jul-25-24 09:40AM
Jul-16-24 04:01PM
Jul-02-24 01:27PM
Jun-06-24 07:00AM
May-08-24 12:06PM
07:43AM
(Thomson Reuters StreetEvents)
04:06AM
May-07-24 10:56PM
05:15PM
04:11PM
(Associated Press Finance)
04:01PM
Apr-30-24 07:00AM
08:00AM
Loading…
Apr-23-24 08:00AM
Apr-05-24 09:40AM
Mar-20-24 09:40AM
Mar-14-24 08:45AM
Mar-04-24 12:00PM
09:40AM
Feb-27-24 09:35AM
08:38AM
(Associated Press Finance)
07:00AM
Feb-15-24 10:00AM
Feb-13-24 09:40AM
Jan-17-24 11:14AM
Jan-16-24 07:00AM
Jan-10-24 07:00AM
Jan-04-24 09:40AM
Dec-19-23 04:01PM
(GlobeNewswire) +8.78%
-8.33%
Dec-05-23 04:01PM
Dec-04-23 09:35AM
Nov-16-23 09:35AM
Nov-14-23 10:57AM
Nov-13-23 07:17AM
07:06AM
07:00AM
Nov-06-23 08:03AM
07:06AM
(Associated Press Finance)
07:00AM
Oct-03-23 07:00AM
Sep-20-23 07:00AM
Sep-18-23 07:00AM
Sep-14-23 07:03PM
(Motley Fool) +5.54%
-5.62%
Sep-08-23 05:06PM
Aug-10-23 06:07AM
Aug-08-23 08:40AM
Aug-07-23 08:15AM
07:10AM
07:00AM
Aug-01-23 07:53AM
Jul-06-23 08:19AM
Jun-26-23 10:15AM
Jun-13-23 06:30PM
07:01AM
Jun-02-23 07:00AM
May-18-23 01:50PM
May-10-23 06:04AM
May-08-23 11:55PM
(Thomson Reuters StreetEvents) -6.46%
08:15AM
07:08AM
07:00AM
May-05-23 06:49AM
May-02-23 07:01AM
Apr-27-23 04:35AM
Apr-24-23 02:37PM
Apr-04-23 07:40AM
Mar-27-23 07:00AM
Mar-10-23 11:34AM
(American City Business Journals)
Mar-06-23 03:59PM
02:32PM
01:03PM
11:50AM
07:00AM
Feb-23-23 08:35AM
07:00AM
Feb-22-23 06:01AM
Feb-09-23 04:01PM
Jan-06-23 07:01AM
Nov-29-22 07:00AM
Nov-26-22 01:39PM
(American City Business Journals)
Nov-22-22 04:01PM
Nov-16-22 12:10PM
Nov-10-22 04:01PM
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Mehra Anand Director Nov 19 '24 Buy 2.25 666,666 1,499,998 710,030 Nov 20 04:20 PM Walker Neal INTERIM PRESIDENT AND CEO Aug 09 '24 Option Exercise 0.72 43,548 31,355 1,356,153 Aug 13 04:15 PM Leonard Braden Michael 10% Owner Aug 05 '24 Buy 1.24 206,025 256,357 14,250,000 Aug 05 03:57 PM Leonard Braden Michael 10% Owner Aug 02 '24 Buy 1.29 167,544 216,400 14,043,975 Aug 05 03:57 PM Leonard Braden Michael 10% Owner Jul 30 '24 Buy 1.30 173,730 226,370 13,776,421 Jul 31 04:10 PM Leonard Braden Michael 10% Owner Jul 31 '24 Buy 1.33 100,000 132,640 13,876,421 Jul 31 04:10 PM Leonard Braden Michael 10% Owner Jul 18 '24 Buy 1.30 130,317 169,555 13,578,286 Jul 22 04:03 PM Leonard Braden Michael 10% Owner Jul 22 '24 Buy 1.33 17,716 23,557 13,602,691 Jul 22 04:03 PM Leonard Braden Michael 10% Owner Jul 19 '24 Buy 1.30 6,689 8,696 13,584,975 Jul 22 04:03 PM Leonard Braden Michael 10% Owner Jul 03 '24 Buy 1.16 143,288 166,071 13,324,952 Jul 05 02:46 PM Leonard Braden Michael 10% Owner Jul 05 '24 Buy 1.15 123,017 141,334 13,447,969 Jul 05 02:46 PM Leonard Braden Michael 10% Owner Jul 02 '24 Buy 1.14 86,092 98,489 13,181,664 Jul 05 02:46 PM Leonard Braden Michael 10% Owner Jun 28 '24 Buy 1.12 1,201,000 1,348,559 12,988,134 Jul 01 01:39 PM Leonard Braden Michael 10% Owner Jun 27 '24 Buy 1.15 235,000 271,331 11,787,134 Jul 01 01:39 PM Leonard Braden Michael 10% Owner Jul 01 '24 Buy 1.14 107,434 122,185 13,095,572 Jul 01 01:39 PM Leonard Braden Michael 10% Owner Jun 14 '24 Buy 1.17 345,000 402,201 11,352,134 Jun 18 04:04 PM Leonard Braden Michael 10% Owner Jun 17 '24 Buy 1.13 150,000 169,500 11,502,134 Jun 18 04:04 PM Leonard Braden Michael 10% Owner Jun 18 '24 Buy 1.13 50,000 56,505 11,552,134 Jun 18 04:04 PM Leonard Braden Michael 10% Owner Jun 11 '24 Buy 1.08 1,000,000 1,080,000 10,395,934 Jun 13 06:04 PM Leonard Braden Michael 10% Owner Jun 13 '24 Buy 1.15 528,621 607,757 11,007,134 Jun 13 06:04 PM Leonard Braden Michael 10% Owner Jun 12 '24 Buy 1.14 82,579 94,140 10,478,513 Jun 13 06:04 PM Powell Andrew Kenneth William Director Mar 01 '24 Buy 1.23 8,500 10,455 22,863 Mar 05 04:58 PM Powell Andrew Kenneth William Director Mar 04 '24 Buy 1.25 6,000 7,500 28,863 Mar 05 04:58 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite